JournalsHub
.online
Find My Journal
NT

Nicholas C. Turner

Royal Marsden NHS Foundation Trust GB

ORCID iD 0000-0001-8937-0873
1,144
Publications
46,320
Citations
92
H-Index
257
i10-Index
4.78
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Publications

0 total

Homologous recombination deficiency and hemizygosity drive resistance in breast cancer

A. Safonov, Minna K. Lee, David N Brown, L. Boscolo Bielo, Miika Mehine - Nature, 2026
Cited by 7 Semantic Scholar

Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer OA

A. Safonov, Antonio Marra, C. Bandlamudi, Ben O'Leary, B. Wubbenhorst - bioRxiv, 2024
Cited by 13 Semantic Scholar

Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study OA

Nicholas C Turner, A. Laird, M. Telli, H. Rugo, A. Mailliez - npj Breast Cancer, 2023
Cited by 5 Semantic Scholar

Targeting the PI3-kinase pathway in triple negative breast cancer. OA

J. Pascual, Nicholas C Turner, Nicholas C Turner - Annals of Oncology, 2019
Cited by 288 Semantic Scholar

Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies OA

K. Shiu, D. Wetterskog, A. Mackay, R. Natrajan, Maryou B. K. Lambros - Oncogene, 2014
Cited by 28 Semantic Scholar

Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. OA

Andrew N J Tutt, C. Lord, Nuala McCabe, Hannah Farmer, Nicholas C Turner - Cold Spring Harbor Symposia on Quantitative Biology, 2005
Cited by 189 Semantic Scholar

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer Clinical Cancer Research

M. Graeser, Afshan Mccarthy, C. Lord, Kay Savage, M. Hills - Unknown Venue, None
Cited by 0 Semantic Scholar

Homologous recombination deficiency and tumor suppressor heterozygosity mediate resistance to front-line therapy in breast cancer

A. Safonov, Antonio Marra, C. Bandlamudi, Ben O'Leary, B. Wubbenhorst - Unknown Venue, None
Cited by 0 Semantic Scholar

Research Topics

Advanced Breast Cancer Therapies (492) Cancer Genomics and Diagnostics (271) HER2/EGFR in Cancer Research (161) Cancer Treatment and Pharmacology (143) PARP inhibition in cancer therapy (124)

Affiliations

Université Paris-Sud
FR 2019 - 2013
AstraZeneca (United Kingdom)
GB 2019 - 2019
Roche (Switzerland)
CH 2023 - 2017
National Health Service
GB 2021 - 2009
Cedars-Sinai Medical Center
US 2016 - 2016

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers

Continue on JournalsHub

Put what you just read into practice with these free tools.

Citation Rate Checker
Verify IF, SJR quartile, CiteScore by ISSN.
Indexing Tracker
Confirm Scopus, DOAJ, JCR, OpenAlex status.
Compare Journals
Side-by-side metrics for up to 3 journals.
Find My Journal
Paste your abstract — get matched journals.
ABDC Journal List
Business / management A*, A, B, C tiers.
Browse All Journals
Search 6,300+ journals with full metrics.
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now
Compare 0 Open → Clear
Save your viewing history
You've browsed several journals this session. Sign in to track them in one place and get weekly impact-factor updates.
Save with Google